The CXCR4 inhibitor JM#170, based on endogenous peptides, can effectively induce apoptosis in BCR-ABL1-transformed mouse B cells by activating the endogenous apoptotic pathway through the upregulation of c-Jun, Bim, and Bax genes, demonstrating potential as a novel targeted drug against Ph+ ALL [108]. Here, CXCR4 is linked to acute lymphoblastic leukemia.